Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03972371




Registration number
NCT03972371
Ethics application status
Date submitted
17/05/2019
Date registered
3/06/2019
Date last updated
28/11/2023

Titles & IDs
Public title
The ProVerum First in Man PROVE Study
Scientific title
The ProVerum First in Man PROVE Study
Secondary ID [1] 0 0
CIP-001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Benign Prostatic Hyperplasia 0 0
Condition category
Condition code
Renal and Urogenital 0 0 0 0
Other renal and urogenital disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Devices - The ProVee Urethral Expander System

Experimental: Treatment Group - The ProVee Urethral Expander is implanted into the prostatic urethra to treat BPH symptoms


Treatment: Devices: The ProVee Urethral Expander System
The ProVee Urethral Expander System is supplied as a single use, sterile device and consists of a nitinol expander implant and custom implant delivery system. The delivery system is designed to allow the implant to be deployed under direct vision.
Intervention code [1] 0 0
Treatment: Devices
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Deployment of the Implant
Timepoint [1] 0 0
Immediately after the implant deployment procedure
Primary outcome [2] 0 0
Expansion of the Implant
Timepoint [2] 0 0
Within 24 hours of the implant deployment procedure
Secondary outcome [1] 0 0
Rate of complications e.g. difficulty with urination, related to the implant use peri-procedurally and in the immediate follow up period
Timepoint [1] 0 0
Immediately after the implant deployment procedure, within 24 hours
Secondary outcome [2] 0 0
Rate of complications e.g. pain, difficulty with urination, related to the implant throughout the follow-up period of 2 years
Timepoint [2] 0 0
2 years
Secondary outcome [3] 0 0
Preliminary assessment of the effectiveness of the procedure in alleviating LUTS voiding symptoms
Timepoint [3] 0 0
2 years
Secondary outcome [4] 0 0
Preliminary assessment of the effectiveness of the procedure in improving urinary flow
Timepoint [4] 0 0
2 years

Eligibility
Key inclusion criteria
* Males = 50 years of age
* Moderate-to-severe symptomatic BPH
* IPSS of > 15
* Peak urinary flow rate (Qmax) of <12 mL/s
* Prostate volume of = 30 and =80 cc
* Prostatic urethral lengths = 4cm
Minimum age
50 Years
Maximum age
No limit
Sex
Males
Can healthy volunteers participate?
No
Key exclusion criteria
* A prostatic urethral length of less than 4cm
* A prostatic volume <30cc or >80cc
* An obstructing intravesical prostatic median lobe
* Urinary incontinence due to an incompetent external sphincter
* Urethral pathologies that may prevent insertion of delivery system
* A current symptomatic urinary tract infection
* Current significant visible haematuria
* Patients with known allergy to nickel or titanium
* History of significant medical co-morbidity or prior surgery that may confound the results of the Study
* Another medical condition that would pose an unacceptable patient risk
* Known or suspected urological condition that may affected voiding function
* Neurogenic bladder and/or sphincter abnormalities
* Patients with cognitive disabilities unable to understand and give informed consent to the research study

Study design
Purpose of the study
Treatment
Allocation to intervention
Not applicable
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
13/05/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
27/11/2023
Sample size
Target
Accrual to date
Final
10
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
The Royal Melbourne Hospital - Melbourne
Recruitment postcode(s) [1] 0 0
- Melbourne

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
ProVerum Medical
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
A clinical evaluation to assess the safety and performance of the ProVeeTM Urethral Expander System, designed to alleviate the symptoms of Benign Prostatic Hyperplasia (BPH).
Trial website
https://clinicaltrials.gov/study/NCT03972371
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT03972371